Russian Federation in August became the first country to grant regulatory approval for a COVID-19 vaccine, doing so before large-scale trials were complete, to the concern of some in the global scientific community.
"We need to increase production of the first and second vaccine", he said in comments broadcast on state TV. On August 11, 2020, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russian Federation and became the worlds first registered vaccine against COVID-19 based on the human adenoviral vectors platform.
India's vaccines regulator has given the green light for a clinical study of the Russia-developed Covid-19 vaccine.
An expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday recommended granting permission to Dr Reddy's Laboratories for conducting phase 2 clinical trials of the vaccine.
Russian Federation has registered a second vaccine - EpiVacCorona, while a third vaccine has received permission to conduct first and second stages of clinical trials at medical facilities in Novosibirsk, St Petersburg and Kirov. While scientists had raised doubts about SputnIk V's safety and efficacy as Russian President Vladimir Putin announced its development to the world without its data being published and without large-scale trials being conducted, however, later medical journal Lancet had said that two trials of the vaccine in June and July involving 76 participants showed that all the participants developed antibodies to the novel coronavirus without any serious side-effects.
It was previously reported that Dr Reddy's Laboratories re-applied fresh protocol to DCGI in order to seek its approval for conducting phase 2 and 3 clinical trials of the Russian COVID19 vaccine. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr. Reddy's upon regulatory approval in India.